Precision Biologics, Inc.

At #DDIP2025, Philip M. Arlen shared groundbreaking insights on "?????? ?????????????????????? ???? ???????????????????? ???????????????????? ?????????????????? ????????????!" His presentation delved into the latest advancements in targeted therapies, offering a glimpse into the future of precision oncology and immunotherapy. ???????? ?????????? ?????? ???????? ??????????????! #Oncology #CancerResearch #Biopharma #PrecisionMedicine #Immunotherapy #HealthcareInnovation #DDIP2025 #Highlights

???????? ?????????????? ???? ??????????????: ?????????????? ???? ???????? ?????????????????? Carolina Garcia Rizo, PhD, MBA, Board Member at QuantPi, led an engaging panel discussion on "???????? ?????????? ???? ??????????: ???????????????????? ???????????????????? ?????????? ???? ???????? ?????????????????? ????????????????." Experts Panel Ed Addison, Executive Chairman, Cloud Pharmaceuticals, Inc. Philip M Arlen, CEO & Founder, Precision Biologics, Inc. Stay tuned for more! #DrugDiscovery #BiotechStartups #PharmaInnovation #WorldBI2025 #HealthcareLeadership #DDIP2025

Join us at the Drug Discovery Innovation Programme for an exciting session with Philip M Arlen, CEO & Founder of Precision Biologics, Inc. , as he discusses: ?? ??????????: ?????? ?????????????????????? ???? ???????????????????? ???????????????????? ?????????????????? ???????????? ?? 03-04 March 2025 ?? Hilton San Diego Bayfront, CA Don't miss this insightful session on groundbreaking advancements in cancer treatment! ??????????????? ???????? ????????????: https://bit.ly/42Ul1mK ?????????????? ???????? ??????????: https://bit.ly/3ZMI2GI ?????????????? ???? ?????? ??????????: [email protected] #AI #Biotech #drugdiscovery #sciencestudent #steam #phdresearch #biologics #medicinalchem #oncology #bioinformatics #genomics #drugdiscoveryconference2025 #ddip2025 #medicinalchemistry

Join Us at the Drug Discovery Innovation Programme for an Engaging Interactive Panel Discussion! ?? Date: March 3-4, 2025 ?? Location: Hilton San Diego Bayfront, CA ?? ??????????:????????? ?????????? ???? ??????????: ???????????????????? ???????????????????? ?????????? ???? ???????? ?????????????????? ???????????????? ?? ??????????????????: Carolina Garcia Rizo, PhD, MBA (Board Member, Oisin Biotechnologies) ????????????????????: ?? Phillip Ebner (Executive Director, Life Sciences, JPMorganChase & Co.) ?? Ed Addison (Executive Chairman, Cloud Pharmaceuticals, Inc.) ?? Philip M Arlen (CEO & Founder, Precision Biologics, Inc. ) Don't miss this opportunity to explore cutting-edge advancements in drug discovery! ??????????????? ???????? ????????????: https://bit.ly/42Ul1mK ?????????????? ???????? ??????????: https://bit.ly/3ZMI2GI ?????????????? ???? ?????? ??????????: [email protected] #AI #Biotech #drugdiscovery #sciencestudent #steam #phdresearch #biologics #medicinalchem #oncology #bioinformatics #genomics #drugdiscoveryconference2025 #ddip2025 #medicinalchemistry

Are we truly maximizing antigen-specific binding—or settling for suboptimal efficacy? Binding affinity is the backbone of therapeutic monoclonal antibody (mAb) success, yet many fail to reach their full clinical potential. How do we push the boundaries of affinity maturation and precision targeting for better patient outcomes? Join kwong tsang, Chief Scientific Officer at Precision Biologics, Inc. at Antibody Therapeutics Xchange - Philadelphia 2025 on Monday, April 14, as he leads the roundtable "Enhancing Antigen-Specific Binding Affinity for Improved Clinical Efficacy." ?? Key discussion points: ?? Affinity maturation strategies to enhance therapeutic mAb binding ?? Developing anti-carcinoma mAbs targeting O-glycans ?? Mechanisms of action—stimulating innate effector processes & inhibiting key pathways This invitation-only event is exclusively for Senior Scientists and above from biotech and pharma companies with a drug pipeline. For more details on this session or Precision Biologics' advancements in targeted antibody therapies, visit: https://lnkd.in/e2MX2_BY #AntibodyTherapeutics #MonoclonalAntibodies #BiologicsInnovation #CancerImmunotherapy #ProteinEngineering #DrugDevelopment #PrecisionBiologics #hubXchange #Xchanges #Roundtable #RegisterNow

Precision Biologics announces that our Director of Research & Development Massimo Fantini, PhD, will deliver a Poster Presentation on how the development and characterization of our two monoclonal antibodies, (NEO-201 and PB-223) targeting truncated O-glycans expressed specifically by cancer cells, can offer a novel strategy to enhance cancer immunotherapy efficacy. Poster title:?Development of monoclonal antibodies targeting truncated O-glycans expressed specifically by cancer cells offers a novel strategy to enhance cancer immunotherapy efficacy The presentation of the poster will be made in person at JW Marriott Los Angeles L.A. Live, Los Angeles, California, USA, on February 24th, 2025 from 1.45pm to 4pm. Please stop by Poster Session A, poster A009.?? ? Glycosylation is a vital post-translational modification of proteins and lipids in mammalian cells. One glycosylation pattern often disrupted during the process of carcinogenesis is O-glycosylation. O-glycans attached to amino acids on glycosylated proteins are involved in the activation of various physiological processes such as cell adhesion, cell-matrix interactions, cellular signaling, glycoprotein folding, cell differentiation, cell communication. Disruption of O-glycan formation leads to the expression of incomplete or truncated O-glycans on proteins of cancer cells from solid tumors as well as hematological malignancies. This alteration supports tumor progression and is often linked to poor prognosis. Targeting truncated O-glycans expressed specifically by cancer cells could be a promising strategy to enhance the efficacy of cancer immunotherapy, although it could be challenging. We developed two clinical stage monoclonal antibodies (mAbs), NEO-201 and PB-223 (PB-223 has been developed through immune engineering of our previous clinical stage mAb NEO-102) that recognize truncated O-glycans expressed specifically on tumor tissues, sparing healthy tissues. Clinical trial results indicate that NEO-201 demonstrates a manageable safety profile and promising efficacy by facilitating the destruction of both cancer cells and immunosuppressive cells expressing core 1 O-glycans. Flow cytometry and IHC analysis showed that PB-223 binds to core 2 O-glycans expressed by a wider spectrum of human tumor types compared to NEO-102, while sparing normal tissues. PB-223 can also internalize into human cancer cell lines expressing core 2 O-glycans. Additionally, NEO-201 and PB-223 serve as versatile platforms for developing next-generation therapeutics, including CAR-T/CAR-NK cells, T-cell/NK cell engagers, bispecific antibodies, and antibody-drug conjugates (ADCs). ? The PDF of the poster will be available starting from February 24th, 2025, on Precision Biologics’ website at the following link: https://lnkd.in/dJaaAjij

Precision Biologics is pleased to announce that Christina Annunziata has joined our Board of Directors. Dr. Annunziata has been instrumental to the development of our NEO-201 program (humanized IgG1 antibody targeting truncated core 1 O-glycans in solid and liquid tumors). We are excited to continue our relationship with her in this new capacity. Dr. Annunziata’s strong scientific and clinical expertise and integral knowledge of Precision Biologics’ NEO-201 and PB-223 programs will play an instrumental role in achieving successful treatments for patients in multiple types of cancer.

Precision Biologics is pleased to announce that Christina Annunziata has joined our Board of Directors. Dr. Annunziata has been instrumental to the development of our NEO-201 program (humanized IgG1 antibody targeting truncated core 1 O-glycans in solid and liquid tumors). We are excited to continue our relationship with her in this new capacity. Dr. Annunziata’s strong scientific and clinical expertise and integral knowledge of Precision Biologics’ NEO-201 and PB-223 programs will play an instrumental role in achieving successful treatments for patients in multiple types of cancer.

Precision Biologics announces that a poster presentation on the affinity maturation and characterization of its novel core 2 O-glycan epitope targeting anti-human carcinoma monoclonal antibody PB-223 will be delivered to the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting on November 7-8, 2024 ?? Poster title: Affinity Maturation and Characterization of a Novel O-glycan Epitope Targeting?Anti-Human Carcinoma Monoclonal Antibody (mAb) PB-223? The presentation of the poster will be made in person at George R. Brown Convention Center, Houston, Texas, USA on the following dates and locations:? ? November 7th, 2024: SITC Immune Engineering Workshop, 3.10 p.m-5 p.m. CST, George R. Brown Convention Center, Level 3 - Grand Ballroom AB, Houston, Texas, USA November 8th, 2024: Poster Session Immuno-Engineering, abstract number 1101, 12:15–1:45 p.m. CST and 5:30-7 p.m. CST, George R. Brown Convention Center, Level 1-Exhibit Halls A B, Houston, Texas, USA? ? Please stop by both dates and locations to discuss these novel findings. Further details about these novel findings and the PDF of the poster can be found in the PR from Precision Biologics at the following link https://lnkd.in/dJQC47Qi

???????????????????????? ???????????????? ???????? ?????????????? Meet our distinguished speakers at the Drug Discovery Innovation Programme, 03-04 March 2025 in San Diego, CA! Join our industry-leading experts as they share breakthrough insights and cutting-edge developments shaping the future of drug discovery. ??????’?? ???????? ???????? ???????????? ???? ?????????? ???????? ?????? ?????????????? ???????? ?????????????? ???? ?????? ?????????????????? ???? ????????????????????! ?????????????? ???????? ??????????: https://bit.ly/3ZMI2GI ?????? ???????????????????? ??????????????: https://bit.ly/4ac9Shb ?????????????? ???? ?????? ??????????: [email protected] #drugdiscovery #innovation #genomics #sciencestudent #steam #scientist #phdresearch #biologics #medicinalchem #drugdiscovery #oncology #bioinformatics #genomics #medicinalchemistry #drugdiscoveryconference2k25 #ddip2k25 Pranav Mathur | Cirsium Biosciences | A Anand Ojha, Ph.D. | Genentech | Zoran Krunic | Amgen | Philip M Arlen | Precision Biologics, Inc.